iCell Therapeutics is a biotechnology company dedicated to establishing new standards of care in oncology and cardiovascular treatments. Cell's proprietary site selective Low Density Emulsion technology and products are backed by more than 16 years of research. iCell has entered into a collaborative research agreement with clinical and academic scientists based at the BC Cancer Agency.